New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 20, 2014
09:00 EDTOHRPOhr Pharmaceutical announces positive case report on Squalamine
Ohr Pharmaceutical announced that a case report on the first patient treated in an ongoing investigator sponsored trial with Squalamine eye drops in proliferative diabetic retinopathy was presented at the 37th Annual Macula Society Meeting, in Key Largo, Florida. Diabetic retinopathy is the second most common cause of vision loss. In PDR, abnormal blood vessels grow from the retina into the vitreous cavity of the eye, resulting in blindness if untreated. This ongoing 5 patient OHR-003 trial is designed to determine the efficacy of topical Squalamine Lactate Ophthalmic Solution, 0.2%, in the treatment of retinal neovascularization resulting from proliferative diabetic retinopathy. The endpoints include regression of neovascularization, anatomical measurements, visual acuity, and safety parameters.
News For OHRP From The Last 14 Days
Check below for free stories on OHRP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 22, 2014
07:25 EDTOHRPOhr Pharmaceutical management to meet with Brean Capital
Subscribe for More Information
July 11, 2014
16:14 EDTOHRPVisium Asset reports 5.2% passive stake in Ohr Pharmaceutical

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use